Interferons

Aktuelle Version vom 11. April 2021, 16:51 Uhr

32301957 ä. Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19
32275914 2020. Type 1 interferons as a potential treatment against COVID-19
32360182 2020. Antiviral activities of type I interferons to SARS-CoV-2 infection
32289152 2020. COVID-19 and emerging viral infections: The case for interferon lambda
32333818 2020. COVID-19: lambda interferon against viral load and hyperinflammation
21093489 2011. (x)Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model
32483527 2020. Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a.
32535509 2020. COVID-19, interferons, and depression: A commentary.
32401715 2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
32526507 2020. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.
32445881 2020. Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.

32610043 2020. Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells.
32532353 2020. Interferon beta-1a for COVID-19: critical importance of the administration route.
32559285 2020. Interferon-beta 1a inhibits SARS-CoV-2 in vitro when administered after virus infection.
32401712 2020. Interferon beta-1b for COVID-19.
32587093 2020. Inhibition of SARS-CoV-2 by type I and type III interferons.
32544867 2020. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.
32544570 2020. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon beta-1b.
32574289 2020. Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?
32574262 2020. Interferon-alpha2b Treatment for COVID-19.
23594967 2013. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin.
32409740 2020. Type I and type III interferon in opposition?
32443163 2020. Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.
32645630 2020. Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.
32646977 2020. Can interferons stop COVID-19 before it takes hold?
32655578 2020. Three Decades of Interferon-beta in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
32661006 2020. Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial.
32665127 ?. Are we fully exploiting type I Interferons in today s fight against COVID-19 pandemic?
32672049 2020. Reply to Jakovac: COVID-19, vitamin D, and type I interferon.
32707096 2020. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
32748578 2020. Interferon-alpha2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study.
32765274 2020. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
32805303 2020. Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon?
32862111 2020. Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial.
32960147 2020. Therapeutic Effectiveness of Interferon-alpha2b Against COVID-19: The Cuban Experience.
33029193 2020. Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy.
33129578 2020. May interferon lambda be a novel therapeutic approach against COVID-19?
33181328 2020. Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia.
33189160 2020. Nebulised interferon beta-1a for patients with COVID-19.
33189161 2020. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.
33219050 2020. Interferon therapy for COVID-19 and emerging infections: Prospects and concerns.
33221168 2020. Potential role of interferons in treating COVID-19 patients.
33222314 2020. PCSK9 inhibitors for COVID-19: An opportunity to enhance the antiviral action of interferon in patients with hypercholesterolemia.
33240967 2020. Bovine Interferon Lambda Is a Potent Antiviral Against SARS-CoV-2 Infection in vitro.
32699094 2020. Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
32707230 2020. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: implications for treatment with IFN-beta and IFN inducer.
32838238 2020. A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-kappa plus TFF2 in patients with moderate COVID-19.
32984784 2020. An open-label, randomized trial of the combination of IFN-kappa plus TFF2 with standard care in the treatment of patients with moderate COVID-19.
33008327 2020. Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study.
33289002 2020. Enhancement of the IFN-beta-induced host signature informs repurposed drugs for COVID-19.